Summary

Persistence Market Research has recently published a detailed report on the global regenerative therapies market. This report offers an in-depth assessment of key market dynamics such as drivers, trends, opportunities, and challenges, delivering crucial insights into the market landscape.

Key Insights:

• Regenerative Therapies Market Size (2024E): USD 31.5 Bn
• Projected Market Value (2033F): USD 123.1 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 21.5%

Regenerative Therapies Market - Report Scope:

Regenerative therapies represent a revolutionary advancement in medical treatment aimed at repairing or replacing damaged tissues and organs through biological processes. This field includes various approaches such as stem cell therapy, gene therapy, tissue engineering, and regenerative medicine. Key market drivers include the rising prevalence of chronic diseases, progress in cellular and molecular biology, and an increased demand for personalized medicine. These therapies provide potential solutions for previously untreatable conditions, offering significant opportunities for innovation and market growth.

Market Growth Drivers:

The global regenerative therapies market is propelled by several factors, including the increasing incidence of chronic and degenerative diseases, advancements in stem cell research, and heightened investment in R&D. The growth of personalized medicine and targeted treatments has spurred the development of novel regenerative therapies, enhancing patient outcomes and quality of life. Furthermore, supportive government regulations and funding initiatives are promoting market expansion and encouraging the development and commercialization of new therapies. The integration of cutting-edge technologies such as CRISPR and tissue engineering is also advancing the effectiveness and scope of regenerative treatments.

Market Restraints:

Despite promising growth potential, the regenerative therapies market encounters challenges such as high development costs, regulatory obstacles, and ethical concerns. The substantial investment required for research and clinical trials can affect the affordability and accessibility of these treatments. The regulatory approval process for new therapies is often lengthy and complex, demanding adherence to rigorous safety and efficacy standards. Additionally, ethical issues related to stem cell research and genetic modifications present challenges to market growth and acceptance.

Market Opportunities:

The regenerative therapies market presents significant growth opportunities driven by technological advancements, increased healthcare spending, and growing patient awareness. The development of new therapies and the expansion of clinical applications create fresh prospects for market growth. Furthermore, partnerships between biotechnology firms, research institutions, and healthcare providers are crucial for driving innovation and accelerating the development of new treatments. The heightened focus on regenerative medicine for sports injuries, orthopedic conditions, and age-related diseases further expands the market scope and attracts investment.

Key Questions Answered in the Report:

• What are the main factors fueling the global growth of the regenerative therapies market?
• Which regenerative therapy approaches are gaining traction across different regions?
• How are technological advancements influencing the competitive landscape of the regenerative therapies market?
• Who are the leading players in the regenerative therapies market, and what strategies are they using to maintain their market position?
• What are the emerging trends and future outlooks in the global regenerative therapies market?

Competitive Intelligence and Business Strategy:

Top players in the global regenerative therapies market, including companies like Stemcell Technologies, Allogene Therapeutics, and Bluebird Bio, focus on innovation, product differentiation, and strategic partnerships to gain a competitive advantage. These companies invest heavily in R&D to develop advanced therapies, improve clinical outcomes, and address unmet medical needs. Collaborations with academic institutions, research organizations, and healthcare providers facilitate technology transfer and commercialization. Emphasizing patient safety, treatment efficacy, and personalized care drives market growth and enhances the commercial viability of regenerative therapies.

Key Companies Profiled:

• AstraZeneca
• GlaxoSmithKline (GSK)
• Bristol-Myers Squibb Company
• Organogenesis Inc.
• Genzyme
• Takara Bio Inc.
• Novartis AG
• Eli Lilly and Company
• NuVasive, Inc.
• Athersys, Inc.
• Mesoblast Ltd
• Cytori Therapeutics Inc.
• 3M

Key Segments of Regenerative Therapies Industry Research

By Therapy Types:

• Cell Therapy
• Stem Cell Therapy
• Tissue engineering
• Gene Therapy

By Application:

• Wound Care
• Musculoskeletal
• Oncology
• Dental
• DMD (Duchenne Muscular Dystrophy)
• Hepatological Diseases
• Inflammatory & Autoimmune Diseases

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Therapy Adoption / Usage Analysis
4.2. Key Promotional Strategies, By Key Manufacturers
4.3. Pipeline Assessment
4.4. Regulatory Landscape
4.5. Disease Epidemiology
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Life Science Industry Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Cancer awareness
5.2.2. Technological Advancements
5.2.3. Prevalence of Targeted Diseases
5.2.4. Therapy Adoption Rate
5.2.5. Cost of Therapy
5.2.6. Strategic Mergers and Acquisitions Among Local
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. COVID19 and Impact Analysis
6.1.1. By Therapy
6.1.2. By Application
6.1.3. By Country
6.2. 2024 Market Scenario
7. Global Regenerative Therapies Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2031
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031, By Therapy
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Therapy, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy, 2024-2031
8.3.1. Cell Therapy
8.3.1.1. Autologous Cell Therapy
8.3.1.2. Allogenic Cell Therapy
8.3.2. Stem Cell Therapy
8.3.2.1. Allogeneic Stem Cell Therapy
8.3.2.2. Autologous Stem Cell Therapy
8.3.3. Tissue-engineering
8.3.4. Gene Therapy
8.4. Market Attractiveness Analysis By Therapy
9. Global Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031, By Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Application, 2024-2031
9.3.1. Wound Care
9.3.2. Musculoskeletal
9.3.3. Oncology
9.3.4. Dental
9.3.5. DMD (Duchenne Muscular Dystrophy)
9.3.6. Hepatological Diseases
9.3.7. Inflammatory & Autoimmune Diseases
9.3.8. Other Therapeutic Applications
9.4. Market Attractiveness Analysis By Application
10. Global Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031, By Region
10.1. Introduction
10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Region, 2024-2031
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Therapy
11.3.3. By Application
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Therapy
11.4.3. By Application
11.5. Market Trends
11.6. Key Market Participants - Intensity Mapping
11.7. Drivers and Restraints - Impact Analysis
11.8. Country Level Analysis & Forecast
11.8.1. U.S. Regenerative Therapies Market Analysis
11.8.1.1. .Introduction
11.8.1.2. Market Analysis and Forecast by Market Taxonomy
11.8.1.2.1. By Therapy
11.8.1.2.2. By Application
11.8.2. Canada Regenerative Therapies Market Analysis
11.8.2.1. Introduction
11.8.2.2. Market Analysis and Forecast by Market Taxonomy
11.8.2.2.1. By Therapy
11.8.2.2.2. By Application
12. Latin America Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
12.3.1. By Country
12.3.1.1. Mexico
12.3.1.2. Brazil
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Therapy
12.3.3. By Application
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Therapy
12.4.3. By Application
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. Mexico Regenerative Therapies Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Therapy
12.8.1.2.2. By Application
12.8.2. Brazil Regenerative Therapies Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Therapy
12.8.2.2.2. By Application
12.8.3. Argentina Regenerative Therapies Market Analysis
12.8.3.1. Introduction
12.8.3.2. Market Analysis and Forecast by Market Taxonomy
12.8.3.2.1. By Therapy
12.8.3.2.2. By Application
13. Europe Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Therapy
13.3.3. By Application
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Therapy
13.4.3. By Application
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Germany Regenerative Therapies Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Therapy
13.8.1.2.2. By Application
13.8.2. Italy Regenerative Therapies Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. B By Therapy
13.8.2.2.2. By Application
13.8.3. France Regenerative Therapies Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Therapy
13.8.3.2.2. By Application
13.8.4. U.K. Regenerative Therapies Market Analysis
13.8.4.1. Introduction
13.8.4.2. Market Analysis and Forecast by Market Taxonomy
13.8.4.2.1. By Therapy
13.8.4.2.2. By Application
13.8.5. Spain Regenerative Therapies Market Analysis
13.8.5.1. Introduction
13.8.5.2. Market Analysis and Forecast by Market Taxonomy
13.8.5.2.1. By Therapy
13.8.5.2.2. By Application
13.8.6. BENELUX Regenerative Therapies Market Analysis
13.8.6.1. Introduction
13.8.6.2. Market Analysis and Forecast by Market Taxonomy
13.8.6.2.1. By Therapy
13.8.6.2.2. By Application
13.8.7. Russia Regenerative Therapies Market Analysis
13.8.7.1. Introduction
13.8.7.2. Market Analysis and Forecast by Market Taxonomy
13.8.7.2.1. By Therapy
13.8.7.2.2. By Application
14. East Asia Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Therapy
14.3.3. By Application
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Therapy
14.4.3. By Application
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. China Regenerative Therapies Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Therapy
14.8.1.2.2. By Application
14.8.2. Japan Regenerative Therapies Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Therapy
14.8.2.2.2. By Application
14.8.3. South Korea Regenerative Therapies Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Therapy
14.8.3.2.2. By Application
15. South Asia Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Therapy
15.3.3. By Application
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Therapy
15.4.3. By Application
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. India Regenerative Therapies Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Therapy
15.8.1.2.2. By Application
15.8.2. Indonesia Regenerative Therapies Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Therapy
15.8.2.2.2. By Application
15.8.3. Malaysia Regenerative Therapies Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Therapy
15.8.3.2.2. By Application
15.8.4. Thailand Regenerative Therapies Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Therapy
15.8.4.2.2. By Application
16. Oceania Regenerative Therapies Market 2019-2023 and Forecast 2024-2031
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Therapy
16.3.3. By Application
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Therapy
16.4.3. By Application
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Australia Regenerative Therapies Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Therapy
16.8.1.2.2. By Application
16.8.2. New Zealand Regenerative Therapies Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Therapy
16.8.2.2.2. By Application
17. Middle East and Africa (MEA) Regenerative Therapies Market Analysis 2019-2023 and Forecast 2024-2031
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2031
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. South Africa
17.3.1.4. North Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Therapy
17.3.3. By Application
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Therapy
17.4.3. By Application
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. GCC Countries Regenerative Therapies Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Therapy
17.8.1.2.2. By Application
17.8.2. North Africa Regenerative Therapies Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Therapy
17.8.2.2.2. By Application
17.8.3. Turkey Regenerative Therapies Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Therapy
17.8.3.2.2. By Application
17.8.4. South Africa & North Africa Regenerative Therapies Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Therapy
17.8.4.2.2. By Application
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis
18.3.1. By Regional Footprint of Players
18.3.2. By Channel Footprint of Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. AstraZeneca
19.3.1.1. Overview
19.3.1.2. Product Portfolio
19.3.1.3. Key Financials
19.3.1.4. Sales Footprint
19.3.1.5. SWOT Analysis
19.3.1.6. Strategy Overview
19.3.1.6.1. Marketing Strategy
19.3.1.6.2. Channel Strategy
19.3.2. GlaxoSmithKline (GSK)
19.3.2.1. Overview
19.3.2.2. Product Portfolio
19.3.2.3. Key Financials
19.3.2.4. Sales Footprint
19.3.2.5. SWOT Analysis
19.3.2.6. Strategy Overview
19.3.2.6.1. Marketing Strategy
19.3.2.6.2. Channel Strategy
19.3.3. Bristol-Myers Squibb Company
19.3.3.1. Overview
19.3.3.2. Product Portfolio
19.3.3.3. Key Financials
19.3.3.4. Sales Footprint
19.3.3.5. SWOT Analysis
19.3.3.6. Strategy Overview
19.3.3.6.1. Marketing Strategy
19.3.3.6.2. Channel Strategy
19.3.4. Organogenesis Inc.
19.3.4.1. Overview
19.3.4.2. Product Portfolio
19.3.4.3. Key Financials
19.3.4.4. Sales Footprint
19.3.4.5. SWOT Analysis
19.3.4.6. Strategy Overview
19.3.4.6.1. Marketing Strategy
19.3.4.6.2. Channel Strategy
19.3.5. Genzyme
19.3.5.1. Overview
19.3.5.2. Product Portfolio
19.3.5.3. Key Financials
19.3.5.4. Sales Footprint
19.3.5.5. SWOT Analysis
19.3.5.6. Strategy Overview
19.3.5.6.1. Marketing Strategy
19.3.5.6.2. Channel Strategy
19.3.6. Takara Bio Inc.
19.3.6.1. Overview
19.3.6.2. Product Portfolio
19.3.6.3. Key Financials
19.3.6.4. Sales Footprint
19.3.6.5. SWOT Analysis
19.3.6.6. Strategy Overview
19.3.6.6.1. Marketing Strategy
19.3.6.6.2. Channel Strategy
19.3.7. Novartis AG
19.3.7.1. Overview
19.3.7.2. Product Portfolio
19.3.7.3. Key Financials
19.3.7.4. Sales Footprint
19.3.7.5. SWOT Analysis
19.3.7.6. Strategy Overview
19.3.7.6.1. Marketing Strategy
19.3.7.6.2. Channel Strategy
19.3.8. Eli Lilly and Company
19.3.8.1. Overview
19.3.8.2. Product Portfolio
19.3.8.3. Key Financials
19.3.8.4. Sales Footprint
19.3.8.5. SWOT Analysis
19.3.8.6. Strategy Overview
19.3.8.6.1. Marketing Strategy
19.3.8.6.2. Channel Strategy
19.3.9. NuVasive, Inc.
19.3.9.1. Overview
19.3.9.2. Product Portfolio
19.3.9.3. Key Financials
19.3.9.4. Sales Footprint
19.3.9.5. SWOT Analysis
19.3.9.6. Strategy Overview
19.3.9.6.1. Marketing Strategy
19.3.9.6.2. Channel Strategy
19.3.10. Athersys, Inc.
19.3.10.1. Overview
19.3.10.2. Product Portfolio
19.3.10.3. Key Financials
19.3.10.4. Sales Footprint
19.3.10.5. SWOT Analysis
19.3.10.6. Strategy Overview
19.3.10.6.1. Marketing Strategy
19.3.10.6.2. Channel Strategy
19.3.11. Mesoblast Ltd
19.3.11.1. Overview
19.3.11.2. Product Portfolio
19.3.11.3. Key Financials
19.3.11.4. Sales Footprint
19.3.11.5. SWOT Analysis
19.3.11.6. Strategy Overview
19.3.11.6.1. Marketing Strategy
19.3.11.6.2. Channel Strategy
19.3.12. Cytori Therapeutics Inc.
19.3.12.1. Overview
19.3.12.2. Product Portfolio
19.3.12.3. Key Financials
19.3.12.4. Sales Footprint
19.3.12.5. SWOT Analysis
19.3.12.6. Strategy Overview
19.3.12.6.1. Marketing Strategy
19.3.12.6.2. Channel Strategy
19.3.13. 3M
19.3.13.1. Overview
19.3.13.2. Product Portfolio
19.3.13.3. Key Financials
19.3.13.4. Sales Footprint
19.3.13.5. SWOT Analysis
19.3.13.6. Strategy Overview
19.3.13.6.1. Marketing Strategy
19.3.13.6.2. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology